Artikel
Comparison of standard chemo- and radiotherapy versus riluzole treatment on viability of brain tumor stem-like cells in in vitro
Suche in Medline nach
Autoren
-
Milena Ninkovic
- The Translational Neurooncology Research Group, Department of Neurosurgery , Georg-August University Göttingen , Göttingen, Deutschland
-
Swetlana Sperling
- The Translational Neurooncology Research Group, Department of Neurosurgery, Georg-August University Göttingen, Göttingen, Deutschland
-
Thiha Aung
- Center of Plastic, Hand and Reconstructive Surgery, University Medical Center Regensburg, Regensburg, Deutschland
-
Sabine Martin
- Department of Molecular Biology of Neuronal Signals, Max Planck Institute of Experimental Medicine, Göttingen, Deutschland
-
Veit Rohde
- Department of Neurosurgery , Georg-August University Göttingen , Göttingen, Deutschland
| Veröffentlicht: | 9. Juni 2017 |
|---|
Gliederung
Text
Objective: Glioblastoma (GBM) therapy remains focused on maximal surgical resection followed by concurrent radiation and chemotherapy using temozolomide (TMZ). Since a small subpopulation of tumor stem-like cells has the capacity to initiate tumor and mediate radio- and chemoresistance, targeting these cells is a potential model for control of GBM. In our previous study we showed that riluzole, a drug used for the treatment of amyotrophic lateral sclerosis, decreases cell viability of GBM stem like cells. Here we investigated the effect of standard after-operation therapy versus riluzole and their combination on these cells in an in vitro system.
Methods: The effect of TMZ, radiation (5 and 10 Gy) and riluzole as well as their combination on the cell viability of two GBM stem-like cell lines was examined. Viable cell population was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in in vitro assay. Riluzole influence on proliferation was measured using staining with propidium iodide. All experiments were performed in triplicate.
Results: Cell viability of two different GBM stem like cell lines; #11 and #64, derived from primary GBM tissue samples, was significantly reduced after riluzole application. Treatment of the cells with the TMZ or with radiotherapy of 5 or 10 Gy alone did not show an effect. Combination of these two treatments with riluzole confirmed riluzole effect. The percentage of proliferating cells declined with riluzole treatment compared to the untreated control sample (p= 0.022 and p= 0.051).
Conclusion: The results presented in this study demonstrate that riluzole alone, but not TMZ or radiation, significantly inhibits cell viability of two GBM stem like cells. This drug decreases also proliferation of these cells. We suggest riluzole for further examination as potential treatment in GBM therapy.
